# A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema

> **NCT02994771** · PHASE1 · TERMINATED · sponsor: **Herantis Pharma Plc.** · enrollment: 15 (actual)

## Conditions studied

- Secondary Lymphedema

## Interventions

- **DRUG:** Lymfactin® [1 x 10E10 vp]
- **DRUG:** Lymfactin® [1 x 10E11 vp]

## Key facts

- **NCT ID:** NCT02994771
- **Lead sponsor:** Herantis Pharma Plc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06
- **Primary completion:** 2019-02-03
- **Final completion:** 2022-04-05
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2023-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02994771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02994771, "A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02994771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*